Compare BioNTech SE - ADR (BNTX) vs Snowflake Inc (SNOW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNTech SE - ADR vs Snowflake Inc — how do they compare? BioNTech SE - ADR trades at $89.89 (market cap $22.86B), while Snowflake Inc trades at $277.3 (market cap $95.64B). The key difference: Snowflake Inc is far larger — about 4.2× BioNTech SE - ADR's market cap, and Snowflake Inc is trading nearer its 52-week high, BioNTech SE - ADR nearer its low. Which is the better fit depends on your goals.
| BNTX | SNOW | |
|---|---|---|
Market Cap | $22.86B | $95.64B |
Sector | Health | Technology |
52-Week High | $119.34 | $280.16 |
52-Week Low | $83.89 | $121.11 |
Enterprise Value | $6.53B | $95.46B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BioNTech (BNTX) trades at $90.07, down 1.55% today, amid a bearish technical signal and declining revenue trends. The company reported a net loss of $1.14 billion in 2025, with profitability metrics negative, though it maintains a strong cash position of $16.78 billion. Recent news highlights restructuring efforts, including site closures and a $1 billion share buyback, as it pivots focus to oncology pipeline development following reduced COVID-19 vaccine demand.
The outlook remains challenging with persistent losses and competitive pressures, but analyst consensus is bullish with a $129.67 price target. Key risks include execution of the oncology strategy and revenue volatility. The stock's current valuation reflects uncertainty, offering potential upside if pipeline milestones are met, but investors face significant operational and market headwinds.
Snowflake (SNOW) trades at $268.65, up 2.75% with strong technical momentum and bullish moving average signals. The company demonstrates robust revenue growth, reaching $3.63 billion in 2025, though remains unprofitable with a -23.79% net margin. Recent quarterly earnings consistently beat expectations, with Q1 2026 EPS of $0.39 surpassing the $0.3193 estimate. Analyst sentiment remains overwhelmingly positive with 42 buy ratings and a $297.35 consensus price target, representing 10.7% upside potential.
Snowflake's outlook remains promising due to accelerating AI Data Cloud adoption and 30% revenue growth targets, but faces risks from premium valuation (P/S 18.19), intense cloud competition, and persistent profitability challenges. The stock's current technical positioning near pivot point resistance at $269 requires monitoring for breakout confirmation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BioNTech SE - ADR
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies.
Read more on BNTX →About Snowflake Inc
Founded in 2012, Snowflake is a data lake, warehousing, and sharing company that came public in 2020. To date, the company has over 3,000 customers including nearly 30% of the Fortune 500 as its customers. Snowflake's data lake stores unstructured and semistructured data that can then be used in analytics to create insights stored in its data warehouse. Snowflake's data sharing capability allows enterprises to easily buy and ingest data almost instantaneously compared with a traditionally months-long process. Overall, the company is known for the fact that all of its data solutions that can be hosted on various public clouds.
Read more on SNOW →
